SCHEMBL3589417

SCHEMBL3589417

CN(C(=O)O)C1CCN(Cc2ccc(-c3ccc(F)cc3)cc2F)CC1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.52
TDP1 Q9NUW8 1/20 0.52
CCR3 P51677 1/20 0.47
KDM4E B2RXH2 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
ACHE P22303 2/20 0.45
BCHE P06276 1/20 0.45
BACE1 P56817 1/20 0.45
SIGMAR1 Q99720 1/20 0.44
CCR5 P51681 3/20 0.43
CXCR3 P49682 2/20 0.43
KCNH2 Q12809 1/20 0.43
GPR119 Q8TDV5 1/20 0.43
HRH3 Q9Y5N1 1/20 0.41
MCHR1 Q99705 1/20 0.40
GRM2 Q14416 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3592324 0.89 ACHE (0.47) ALDH1A1TDP1CCR3KDM4ESMN1; SMN2
SCHEMBL3589414 0.77 KMT2A (0.53) ALDH1A1TDP1CCR3ACHEBCHE
SCHEMBL16858885 0.77 ROCK1 (0.48) ALDH1A1TDP1CCR3ACHEBCHE
SCHEMBL2972293 0.77 ALDH1A1 (0.42) ALDH1A1TDP1ACHEBCHEBACE1
SCHEMBL3935459 0.76 CHRM4 (0.59) ALDH1A1TDP1ACHEBCHE
SCHEMBL2972297 0.74 ALDH1A1 (0.43) ALDH1A1TDP1KDM4EACHEBCHE
SCHEMBL3942391 0.74 CHRM4 (0.62) CCR3SIGMAR1CCR5KCNH2HRH3
SCHEMBL27088086 0.74 NR1H2 (0.60) ALDH1A1TDP1CCR3KDM4ESIGMAR1
SCHEMBL2972291 0.72 ALDH1A1 (0.47) ALDH1A1TDP1ACHEBCHEBACE1
SCHEMBL15859873 0.72 MEN1 (0.47) ALDH1A1TDP1CXCR3GRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1720550-B1 DERIVATIVES OF PIPERIDINYLALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS SANOFI AVENTIS (FR) 2009-04-15 EP claimed
US-20100279998-A1 PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS SANOFI-AVENTIS (FR) 2010-11-04 US disclosed
EP-1720550-B1 DERIVATIVES OF PIPERIDINYLALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS SANOFI AVENTIS (FR) 2009-04-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100279998-A1 PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS FAAH, FAAH2, CNR2 ALDH1A1 974/4885TDP1 4251/4885CCR3 1379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.